Comparison of Ectoin® Containing Eye Drops and Ectoin® Containing Eye Spray With the Eye Spray Tears Again®
Launched by BITOP AG · Jul 15, 2019
Trial Information
Current as of May 06, 2025
Completed
Keywords
ClinConnect Summary
The term disorder describes the general development of physical symptoms without vegetative or morphologically detectable impairment.
These disorders cause physical symptoms with different severities and different impairments, e.g. exhaustion, fatigue, headache, stomach and back pain.
The eye might also be prone to disorders. These manifest in symptoms like dry eyes, tightness of the eye lids, foreign body sensation and reddened, burning, itching or watery eyes.
Disorders of the eye can be caused by extensive screen and computer work, air condition, dry heating air or draught, as well as...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- Patients have to meet the following inclusion criteria in order to participate in the study:
- • Signed and dated informed consent form
- • Male and female patients aged 18 to 75 years
- • Patients have to suffer from allergen exposure induced environmental disorder of the eye
- Exclusion Criteria:
- • -
- • Non-inclusion criteria
- • Contraindications according to the package leaflet/summary of product characteristics
- • currently wearing contact lenses
About Bitop Ag
Bitop AG is a biopharmaceutical company focused on the development and commercialization of innovative therapeutic solutions for dermatological and infectious diseases. With a commitment to advancing healthcare through cutting-edge research, Bitop AG specializes in the formulation of novel compounds and the optimization of existing treatments. The company leverages its expertise in pharmacology and biotechnology to conduct rigorous clinical trials, ensuring safety and efficacy while addressing unmet medical needs. Bitop AG is dedicated to improving patient outcomes and enhancing therapeutic options through its collaborative approach and state-of-the-art technology.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Aachen, Nrw, Germany
Patients applied
Trial Officials
Ralph Mösges, Dr.
Study Director
ClinCompetence
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials